Starpharma Holdings Rated 'Speculative Buy/4,' Lead Dendrimer Product Stands At Forefront Of Global HIV/AIDS Prevention Strategies, According To Investrend Research Analyst Sharifzadeh In Initial 'Benchmark' Report.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- (Investrend Research Syndicate)Starpharma Holdings Limited (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). : SPHRY) (ASX ASX See: Australian Stock Exchange : SPL (1) (Systems Programming Language) The assembly language for the HP 3000 series. See assembly language for an SPL program example. (2) (Structured Programming Language) See structured programming. 1. ) has been rated "Speculative Buy/4" by Investrend Research analyst Mohammad Sharifzadeh, CFA (Computer Fraud and Abuse Act of 1986) Signed into law in 1986, the CFA was a significant step forward in criminalizing unauthorized access to computer systems and networks. The Act applies to "federal interest computers" that include any system used by the U.S. , PhD., in his initial "Benchmark" Report on the company. Sharifzadeh is also lead analyst for Investrend's nanotechnology sector research coverage commissioned by Cronus Capital Markets. The full Starpharma report, including important disclosures and disclaimers, is at http://www.investrendresearch.com. In it the analyst stated: "Starpharma Holdings Limited is an emerging company operating in an emerging industry. Starpharma's business strategy is to use dendrimer-based nanotechnology to discover, develop and commercialize pharmaceuticals for serious human diseases. "VivaGel(TM) is Starpharma's lead dendrimer den·dri·mer n. A polymer in which the atoms are arranged in many branches and subbranches along a central backbone of carbon atoms. Also called cascade molecule. product. It is a gel-based microbicide with a nanotech active being developed to prevent sexually transmitted infections in women. "VivaGel[TM] addresses markets with huge potentials. Starpharma's VivaGel stands at the forefront of the global HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome prevention strategies. "VivaGel[TM] has received clearance from the U.S. FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for human clinical trials and the company has already opened the site in the U.S. to recruit volunteers for the clinical trial of VivaGel[TM] for prevention of genital herpes Genital Herpes Definition Genital herpes is a sexually transmitted disease caused by a herpes virus. The disease is characterized by the formation of fluid-filled, painful blisters in the genital area. . "We agree with Starpharma's management that acquisition of DNT DNT Document & Network Technologies DNT Dinitrotoluene DNT Dynamic Network Technologies DNT Do Not Type DNT Dodonu Ni Taukei Party (Fiji political party) DNT Do Not Touch DNT Dialed Number Trigger DNT Do Not Translate results in valuable synergies including more U.S. presence, extensive IP portfolio, road to commercialization, and a more diversified product base. "Starpharma has a healthy balance sheet. They have a strong cash position which can support their operating and R&D expenses should there be a shortfall in revenues. Starpharma has almost a debt free balance sheet with substantial equity which provides the company with the opportunity of external financing should the need arises. "During the Fiscal Year 2006 Starpharma's revenue from government sources was a total of A$6,422,066, almost five times the A$1,409,844 government related revenue in Fiscal year 2005. "Starpharma's major expense item is R&D expense which reflects the Company's active strategy of staying as a leading entity in the dendrimer industry. Starpharma's loss per share decreased from 6.97 Australian Cents in FY05 to 5.69 Australian Cents in FY06." The full report, including important disclosures and disclaimers, is available at http://www.investrendresearch.com, and at the company's InvestorPower Page at http://www.investrend.com/company/Company.asp?id= 1518&sPathParam=yes&sAlias=sphry. (Due to the length of this URL, it may be necessary to copy and paste it into your Internet browser's URL address field. You may also need to remove an extra space in the URL if one exists.) Investors are advised to read those disclosures carefully before trading in the equities of any enrolled company. Starpharma Holdings is enrolled in Investrend Research's pioneering professional research program, which facilitates independent analysts to provide coverage for shareholders in companies that otherwise would have little or no analyst following. Enrollment fees for the "Benchmark" research platform are $26,800, which is being paid by Cronus Capital Markets, a "third party." Analysts are paid in advance for their initial reports by Investrend Research to limit or eliminate pecuniary Monetary; relating to money; financial; consisting of money or that which can be valued in money. pecuniary adj. relating to money, as in "pecuniary loss. interests, and no one associated with the program may own or trade in the equities of companies under coverage. Investrend subscribes to the "Standards of Practice for Research Providers" at http://www.firstresearchconsortium.com, and its research is enrolled for investor monitoring by the not-for-profit Shareholders Research Alliance, Inc. (http://www.shareholdersresearch.com). Anyone interested in receiving alerts regarding Starpharma Holdings research should email contact@investrend.com with "SPHRY" in the subject line. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion